Compare Davita Inc (DVA) vs Fabrinet (FN) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Davita Inc vs Fabrinet — how do they compare? Davita Inc trades at $179.25 (market cap $11.29B), while Fabrinet trades at $486.28 (market cap $17.46B). The key difference: Fabrinet is the larger of the two by market cap, and Davita Inc is trading nearer its 52-week high, Fabrinet nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Davita Inc for 114 Days and Fabrinet for 30 Days on average.
| DVA | FN | |
|---|---|---|
Market Cap | $11.29B | $17.46B |
Volume | 582,204 | 1,199,886 |
Sector | Health | Technology |
52-Week High | $240.96 | $746.47 |
52-Week Low | $103.87 | $361.94 |
Typical Hold Time | 114 Days | 30 Days |
Enterprise Value | $24.01B | $16.59B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
DaVita (DVA) trades at $177.02, up 0.14% with a bearish technical signal despite recent earnings beats. The stock shows strong fundamentals with a P/E of 15 and revenue growth from $13.64B in 2025 to projected $14.0B in 2026. Recent news highlights value-based care expansion with Humana and institutional buying by BlackRock. Technical indicators show resistance at $179 and support at $175, with RSI neutral at 59.72.
DVA presents a mixed outlook: analyst consensus targets $235.67 (33% upside) with 43% buy ratings, but technicals suggest near-term pressure. Key opportunities include consistent EPS beats and partnership growth, while risks involve rising debt-to-asset ratio (65.55% in 2025) and regulatory exposure. Net cash flow turned negative in 2025, requiring monitoring.
Fabrinet (FN) trades at $486.28, down 2.35% today but maintains strong analyst support with 75% buy ratings and a $769.50 consensus price target. The stock shows bullish technical signals with support at $477 and resistance at $498, while recent earnings beats highlight robust AI data-center demand driving 45% revenue growth in Q4 2026. Valuation metrics include a P/E of 37.34 and ROE of 21.33%, reflecting premium pricing for high growth.
Outlook remains positive with multi-year AI infrastructure expansion, though risks include customer concentration and margin pressure from capital expenditures. The stock offers significant upside to analyst targets if execution continues, but volatility may persist near current levels.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Davita Inc
DaVita is the largest provider of dialysis services in the United States, boasting market share that eclipses 35% when measured by both patients and clinics. The firm operates over 3,100 facilities worldwide, mostly in the U.S., and treats over 240,000 patients globally each year. Government payers dominate U.S. dialysis reimbursement. DaVita receives approximately 69% of U.S. sales at government (primarily Medicare) reimbursement rates, with the remaining 31% coming from commercial insurers. However, while commercial insurers represented only about 10% of the U.S. patients treated, they represent nearly all of the profits generated by DaVita in the U.S. dialysis business.
Read more on DVA →About Fabrinet
Fabrinet provides advanced optical and electromechanical manufacturing services to original equipment manufacturers. It specializes in complex products for telecom, automotive, and medical industries.
Read more on FN →
